NCT02428712 2025-07-29A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid TumorsFore BiotherapeuticsPhase 1/2 Completed113 enrolled
NCT04894825 2023-11-27Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in ChinaFutureGen Biopharmaceutical (Beijing) Co., LtdPhase 1 Unknown152 enrolled